objective: the use of fetal hemoglobin (hbf) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. hbf inducers including hydroxyurea, histone deacetylase (hdac) inhibitor agents such as sodium butyrate, azacitidine, decitabine and new immunomodulator drugs like pomalidomide, lenalidomide and thalidomide can redu...
